Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securitie
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira B
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Pacira BioSciences, Inc.(PCRX) Shareholders
02:00am, Wednesday, 15'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 15, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securitie
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit
01:46am, Wednesday, 15'th Jan 2025
NEW YORK , Jan. 15, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of securities of Pacira Bi
Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PCRX
08:30pm, Tuesday, 14'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securitie
Stockholder Notice: Robbins LLP Informs Stockholders of the Pacira BioSciences, Inc. Class Action Lawsuit
08:03pm, Tuesday, 14'th Jan 2025
SAN DIEGO , Jan. 14, 2025 /PRNewswire/ -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, I
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Pacira BioSciences, Inc. ("Pac
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securitie
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action lawsuit on behalf of purchasers of securities o
Lost Money on Pacira BioSciences, Inc.(PCRX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
04:30pm, Tuesday, 14'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securitie
NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed ag
PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm
01:14pm, Tuesday, 14'th Jan 2025
LOS ANGELES--(BUSINESS WIRE)--PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Levi & Korsinsky Notifies Pacira BioSciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PCRX
01:00pm, Tuesday, 14'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securitie
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of March 14, 2025 in Pacira Lawsuit - PCRX
12:00pm, Tuesday, 14'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securitie
ATLANTA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Pacira BioSciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX). The lawsuit alleges th
